A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

L. Fredrik Jarskog; Martin T. Lowy; Richard A. Grove; Richard S E Keefe; Joseph P. Horrigan; M. Patricia Ball; Alan Breier; Robert W. Buchanan; Cameron S Carter; John G. Csernansky; Donald C. Goff; Michael F. Green; Joshua T. Kantrowitz; Matcheri S. Keshavan; Marc Laurelle; Jeffrey A. Lieberman; Stephen R. Marder; Paul Maruff; Robert P. McMahon; Larry J. Seidman; Margaret A. Peykamian

doi:10.1016/j.schres.2015.01.041

A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

L. Fredrik Jarskog, Martin T. Lowy, Richard A. Grove, Richard S E Keefe, Joseph P. Horrigan, M. Patricia Ball, Alan Breier, Robert W. Buchanan, Cameron S Carter, John G. Csernansky, Donald C. Goff, Michael F. Green, Joshua T. Kantrowitz, Matcheri S. Keshavan, Marc Laurelle, Jeffrey A. Lieberman, Stephen R. Marder, Paul Maruff, Robert P. McMahon, Larry J. SeidmanMargaret A. Peykamian

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H<inf>3</inf> receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.

Original language	English (US)
Pages (from-to)	136-142
Number of pages	7
Journal	Schizophrenia Research
Volume	164
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2015.01.041
State	Published - May 1 2015

Keywords

Cognition
CogState Schizophrenia Battery
GSK239512
Histamine H<inf>3</inf> antagonist
MATRICS Consensus Cognition Battery
Schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/j.schres.2015.01.041

Fingerprint Dive into the research topics of 'A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy'. Together they form a unique fingerprint.

Cite this

Jarskog, L. F., Lowy, M. T., Grove, R. A., Keefe, R. S. E., Horrigan, J. P., Ball, M. P., Breier, A., Buchanan, R. W., Carter, C. S., Csernansky, J. G., Goff, D. C., Green, M. F., Kantrowitz, J. T., Keshavan, M. S., Laurelle, M., Lieberman, J. A., Marder, S. R., Maruff, P., McMahon, R. P., ... Peykamian, M. A. (2015). A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research, 164(1-3), 136-142. https://doi.org/10.1016/j.schres.2015.01.041

A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. / Jarskog, L. Fredrik; Lowy, Martin T.; Grove, Richard A.; Keefe, Richard S E; Horrigan, Joseph P.; Ball, M. Patricia; Breier, Alan; Buchanan, Robert W.; Carter, Cameron S; Csernansky, John G.; Goff, Donald C.; Green, Michael F.; Kantrowitz, Joshua T.; Keshavan, Matcheri S.; Laurelle, Marc; Lieberman, Jeffrey A.; Marder, Stephen R.; Maruff, Paul; McMahon, Robert P.; Seidman, Larry J.; Peykamian, Margaret A.

In: Schizophrenia Research, Vol. 164, No. 1-3, 01.05.2015, p. 136-142.

Research output: Contribution to journal › Article › peer-review

Jarskog, LF, Lowy, MT, Grove, RA, Keefe, RSE, Horrigan, JP, Ball, MP, Breier, A, Buchanan, RW, Carter, CS, Csernansky, JG, Goff, DC, Green, MF, Kantrowitz, JT, Keshavan, MS, Laurelle, M, Lieberman, JA, Marder, SR, Maruff, P, McMahon, RP, Seidman, LJ & Peykamian, MA 2015, 'A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy', Schizophrenia Research, vol. 164, no. 1-3, pp. 136-142. https://doi.org/10.1016/j.schres.2015.01.041

Jarskog, L. Fredrik ; Lowy, Martin T. ; Grove, Richard A. ; Keefe, Richard S E ; Horrigan, Joseph P. ; Ball, M. Patricia ; Breier, Alan ; Buchanan, Robert W. ; Carter, Cameron S ; Csernansky, John G. ; Goff, Donald C. ; Green, Michael F. ; Kantrowitz, Joshua T. ; Keshavan, Matcheri S. ; Laurelle, Marc ; Lieberman, Jeffrey A. ; Marder, Stephen R. ; Maruff, Paul ; McMahon, Robert P. ; Seidman, Larry J. ; Peykamian, Margaret A. / A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. In: Schizophrenia Research. 2015 ; Vol. 164, No. 1-3. pp. 136-142.

@article{d2c34f3057ac4a3a8ef19e2b1a0fac3b,

title = "A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy",

abstract = "This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.",

keywords = "Cognition, CogState Schizophrenia Battery, GSK239512, Histamine H<inf>3</inf> antagonist, MATRICS Consensus Cognition Battery, Schizophrenia",

author = "Jarskog, {L. Fredrik} and Lowy, {Martin T.} and Grove, {Richard A.} and Keefe, {Richard S E} and Horrigan, {Joseph P.} and Ball, {M. Patricia} and Alan Breier and Buchanan, {Robert W.} and Carter, {Cameron S} and Csernansky, {John G.} and Goff, {Donald C.} and Green, {Michael F.} and Kantrowitz, {Joshua T.} and Keshavan, {Matcheri S.} and Marc Laurelle and Lieberman, {Jeffrey A.} and Marder, {Stephen R.} and Paul Maruff and McMahon, {Robert P.} and Seidman, {Larry J.} and Peykamian, {Margaret A.}",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.schres.2015.01.041",

language = "English (US)",

volume = "164",

pages = "136--142",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

AU - Jarskog, L. Fredrik

AU - Lowy, Martin T.

AU - Grove, Richard A.

AU - Keefe, Richard S E

AU - Horrigan, Joseph P.

AU - Ball, M. Patricia

AU - Breier, Alan

AU - Buchanan, Robert W.

AU - Carter, Cameron S

AU - Csernansky, John G.

AU - Goff, Donald C.

AU - Green, Michael F.

AU - Kantrowitz, Joshua T.

AU - Keshavan, Matcheri S.

AU - Laurelle, Marc

AU - Lieberman, Jeffrey A.

AU - Marder, Stephen R.

AU - Maruff, Paul

AU - McMahon, Robert P.

AU - Seidman, Larry J.

AU - Peykamian, Margaret A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.

AB - This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.

KW - Cognition

KW - CogState Schizophrenia Battery

KW - GSK239512

KW - Histamine H<inf>3</inf> antagonist

KW - MATRICS Consensus Cognition Battery

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84929292908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929292908&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2015.01.041

DO - 10.1016/j.schres.2015.01.041

M3 - Article

C2 - 25728831

AN - SCOPUS:84929292908

VL - 164

SP - 136

EP - 142

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -